Pharvaris BV (PHVS)

Pharvaris BV (PHVS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.1B; returns 1 day +2.4%, 1 week +13.2%, 1 year +36.6%.

Pharvaris BV is a late-stage biopharmaceutical company headquartered in Leiden, the Netherlands, dedicated to the discovery and development of novel, oral bradykinin B2 receptor antagonists. Its primary focus is on addressing unmet medical needs in patients suffering from hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

Groups PHVS belongs to

• Biotechnology
• Biopharmaceutical
• Healthcare
• Rare Diseases
• Clinical Stage Biopharma
• Unmet Medical Needs
• Pharmaceuticals
• Drug Discovery
• Life Sciences
• Clinical Stage

PHVS financial model: income statement, cash flow and balance sheet